الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 290 |  |  |
| | | from | 290 | | |
Abstract
Background: Irisin is a newly discovered polypeptide hormone, that was reported in many studies as a potential biomarker for the development of obesity, chronic kidney diseases, heart disease, diabetes and stroke.
Aim of the study: This study was undertaken to evaluate the relationship between cord blood irisin level and other parameters as insulin resistance, birth weight and gestational age among neonates.
Methodology: This case control study was conducted on 90 newborns, grouped into 30 small for gestational age (SGA), 30 appropriate for gestational age (AGA) and 30 large for gestational age (LGA) neonates. Umbilical cord blood was collected at time of delivery, for measurement of serum irisin and insulin levels by ELISA technique.
Results: Irisin was significantly highest in LGA, followed by AGA, then SGA (mean was 13.5, 8.5 and 2.1, respectively). Irisin level had a significant negative correlation with insulin and HOMA-IR among LGA group only (r=0.433, p=0.017 and r=0.486, p=0.006, respectively). Serum irisin level was lower in cases with insulin resistance among SGA, AGA and LGA groups (p=0.025, 0.031 and <0.001, respectively). Using Roc curve, irisin had moderate diagnostic characteristics in differentiating SGA and LGA from AGA (cutoff point: ≤5.2 ng/ml and ≥ 8.2 ng/ml, respectively) and in differentiating insulin resistance (cutoff point: ≤ 0.8 ng/ml, ≤ 1.4 ng/ml and ≤ 14.3 ng/ml in SGA, AGA and LGA groups, respectively).
Conclusion: Highest insulin concentration and insulin resistance were significantly associated with LGA neonates. Irisin among the three groups was negatively correlated with insulin and HOMA-IR, with significance only in LGA. Irisin can be used as a screening tool to differentiate SGA from AGA and LGA from AGA neonates and to detect insulin resistance among SGA, AGA and LGA neonates, but cannot be considered a diagnostic tool.